Editas Medicine (EDIT) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Editas Medicine (EDIT) is Neutral.

The composite score behind that read is -0.06, weighing +0.21 of bullish evidence against -0.32 bearish.

Editas Medicine last closed at $2.90, +2.11% on the session.

Against the IVW growth benchmark the position is +1.31% over the forecast window.

The read is built from 15 underlying insights — 2 bullish and 13 bearish.

Agreement across those insights is 87%.

20 graded predictions for EDIT so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Editas Medicine in the 5th percentile on return on equity, where 100 is best.

Editas Medicine is classified under Health Care / Biotechnology, with a market capitalisation of $436.17M.

StockMap tracks Editas Medicine as the 190th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Editas Medicine ranks 156th of 381 in the group, against a group median of -0.08.